Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O S Kofman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1984
Are levodopa "drug holidays" justified?O S Kofman
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1991
Deprenyl: protective vs. symptomatic effectO S Kofman
The New England Journal of Medicine|June 10, 1993
Protective effect or symptomatic effect of deprenyl?O S Kofman
Archives of Neurology|August 1, 1973
A therapeutic paradox? Combined treatment of Parkinson's disease with levodopa and methyldopaO S Kofman
Canadian Family Physician Medecin De Famille Canadien|February 3, 2011
Complications of therapy in Parkinson's diseaseO S Kofman
Applied Therapeutics|April 1, 1970
Diffuse cerebral atrophyO S Kofman, V H Macmillan
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1982
Bromocriptine (ParlodelR) in the treatment of Parkinson's diseaseP Molina-Negro, J D Grimes, M W Jones, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1984
Bromocriptine in the management of end of dose deterioration in Parkinson's diseaseJ D Grimes, D B King, O S Kofman, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1984
Are levodopa "drug holidays" justified?O S Kofman
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1991
Deprenyl: protective vs. symptomatic effectO S Kofman
The New England Journal of Medicine|June 10, 1993
Protective effect or symptomatic effect of deprenyl?O S Kofman
Archives of Neurology|August 1, 1973
A therapeutic paradox? Combined treatment of Parkinson's disease with levodopa and methyldopaO S Kofman
Canadian Family Physician Medecin De Famille Canadien|February 3, 2011
Complications of therapy in Parkinson's diseaseO S Kofman
Applied Therapeutics|April 1, 1970
Diffuse cerebral atrophyO S Kofman, V H Macmillan
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1982
Bromocriptine (ParlodelR) in the treatment of Parkinson's diseaseP Molina-Negro, J D Grimes, M W Jones, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1984
Bromocriptine in the management of end of dose deterioration in Parkinson's diseaseJ D Grimes, D B King, O S Kofman, et al.
Pageof 1